Soleno Therapeutics (SLNO) Total Current Liabilities (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Total Current Liabilities of $200000.0 for Q1 2026, down 98.73% year-over-year from $15.7 million in Q1 2025, and down 99.67% quarter-over-quarter from $61.4 million in Q4 2025.
Soleno Therapeutics (SLNO) Total Current Liabilities (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Total Current Liabilities for 14 consecutive years, with $200000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 98.73% year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $200000.0 (down 98.73% YoY), while the FY2025 annual figure was $61.4 million, up 227.32% from the prior year.
- Total Current Liabilities slipped to $200000.0 in Q1 2026 per SLNO's latest filing, from $61.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $61.4 million in Q4 2025 and bottomed at $200000.0 in Q1 2026.
- Historically, Total Current Liabilities has averaged $16.1 million across 5 years, with a median of $11.5 million in 2023.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 294.89% — and 2026, when it sank 98.73%.
- Soleno Therapeutics' Total Current Liabilities stood at $7.3 million in 2022, then jumped by 57.32% to $11.5 million in 2023, then soared by 62.95% to $18.7 million in 2024, then jumped by 227.32% to $61.4 million in 2025, then plunged by 99.67% to $200000.0 in 2026.
- Business Quant data shows SLNO's Total Current Liabilities at $200000.0 in Q1 2026, $61.4 million in Q4 2025, and $33.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 61.36 Mn |
| Sep 30, 2025 | 33.25 Mn |
| Jun 30, 2025 | 20.94 Mn |
| Mar 31, 2025 | 15.73 Mn |
| Dec 31, 2024 | 18.75 Mn |
| Sep 30, 2024 | 14.96 Mn |
| Jun 30, 2024 | 9.15 Mn |
| Mar 31, 2024 | 13.46 Mn |
| Dec 31, 2023 | 11.51 Mn |
| Sep 30, 2023 | 28.99 Mn |
| Jun 30, 2023 | 8.80 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | 7.31 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | 7.25 Mn |
| Mar 31, 2022 | 7.31 Mn |
| Dec 31, 2021 | 8.01 Mn |
| Sep 30, 2021 | 9.04 Mn |
| Jun 30, 2021 | 8.36 Mn |